Ron Lanton Discusses FDA’s Single-Trial Approval Pathway with Pharmaceutical Executive

Ron Lanton spoke with Pharmaceutical Executive about the FDA’s evolving approach to drug approvals and the potential shift toward a single-trial evidentiary pathway. The discussion examines how changes in regulatory expectations could affect development strategy, litigation exposure, and pricing dynamics across the pharmaceutical sector. As regulatory signals increasingly influence market strategy, companies developing innovative therapies must evaluate not only the scientific strength of their programs but also how evolving FDA policy may shape investor expectations and commercialization timelines. Listen to the interview here.